Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 1;19:124. doi: 10.1186/s12951-021-00865-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 5 — Co-administration of anti-tumor efficacy In vivo. a Treatment scheme of subcutaneous Hepa1-6 tumors with CA4-NPs and aPD-L1; b Tumor volume growth curves following different treatments; c Representative images of the excised tumors after different treatments; shown are PBS-treated mice and mice receiving after injection with CA4-NPs (20 mg kg⁻¹), CA4-NPs (40 mg kg⁻¹), aPD-L1, CA4-NPs (20 mg kg⁻¹) + aPD-L1, CA4-NPs (40 mg kg⁻¹) + aPD-L1; d Tumor weights from the different groups on day 15; e The survival percentages of the tumor-bearing C57BL/6 mice (n = 7 biologically independent samples). Significance between each pair of groups was calculated using Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. The values are presented as the mean ± SD, n = 10

Fig. 5 — Co-administration of anti-tumor efficacy In vivo. a Treatment scheme of subcutaneous Hepa1-6 tumors with CA4-NPs and aPD-L1; b Tumor volume growth curves following different treatments; c Representative images of the excised tumors after different treatments; shown are PBS-treated mice and mice receiving after injection with CA4-NPs (20 mg kg⁻¹), CA4-NPs (40 mg kg⁻¹), aPD-L1, CA4-NPs (20 mg kg⁻¹) + aPD-L1, CA4-NPs (40 mg kg⁻¹) + aPD-L1; d Tumor weights from the different groups on day 15; e The survival percentages of the tumor-bearing C57BL/6 mice (n = 7 biologically independent samples). Significance between each pair of groups was calculated using Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. The values are presented as the mean ± SD, n = 10